Examkin

Question

Difficulty: HardStudy Design

A clinical research consortium is planning a randomized crossover trial to assess the efficacy of a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist for chronic migraine prophylaxis. According to the protocol, participants will be randomly assigned to receive either the active CGRP antagonist or a visually identical placebo for 12 weeks. Following this initial phase, the groups will switch therapies for an additional 12 weeks. During the protocol review, the lead methodologist mandates the inclusion of a 6-week interval between the two 12-week treatment periods. During this 6-week interval, participants will receive neither the active drug nor the placebo, but may use standard abortive medications as needed.

If this 6-week interval is omitted from the final study design, the internal validity of the trial will be most directly threatened by which of the following?

  1. The persistent pharmacological or physiological influence of the initial intervention on outcomes measured during the subsequent phase.Answer
  2. B
    The unequal distribution of unmeasured baseline confounding variables between the groups assigned to the two different treatment sequences.
  3. C
    The tendency for participants who enrolled with unusually high migraine frequencies to naturally improve toward their long-term average.
  4. D
    The alteration of participant reporting behavior resulting from their awareness of being actively monitored in a clinical trial.
  5. E
    The differential loss to follow-up occurring if one treatment sequence is systematically less tolerable than the alternative sequence.

Answer

The persistent pharmacological or physiological influence of the initial intervention on outcomes measured during the subsequent phase.
The correct answer accurately describes a carryover effect. In a crossover study design, each participant serves as their own control by receiving both the experimental treatment and the control sequentially. A major vulnerability of this design is the carryover effect, where the pharmacological or physiological effects of the first treatment persist into the second treatment period, thereby distorting the outcome measurements of the second intervention. To mitigate this threat to internal validity, a washout period (the 6-week interval) is mandated to allow the first drug to be completely eliminated and the patient's physiology to return to baseline before the second phase begins.

Step-by-Step Solution

1
Analyze the study design described in the vignette.
The study is a randomized crossover trial where patients receive treatment A then B, or treatment B then A, with a planned gap between phases.
Identifying the architectural framework of the study is the first step in recognizing its specific methodological vulnerabilities.
2
Identify the specific design element in question.
The question asks about the purpose of the 6-week interval between the two active treatment periods, which is epidemiologically known as a 'washout period'.
Connecting the scenario's practical description (a 6-week break) to its formal epidemiological term enables accurate analysis of its function.
3
Determine the specific threat to internal validity prevented by this element.
A washout period prevents the residual effects of the first treatment from contaminating the baseline state and outcome measurements of the second treatment phase, a phenomenon known as the carryover effect.
This is a fundamental requirement of crossover designs to ensure that the outcome during the second phase is entirely attributable to the second intervention.
4
Match this phenomenon to the correct descriptive option.
The correct option correctly describes the mechanism of a carryover effect.
Examining each option confirms that only one describes the temporal carryover of pharmacological influence.

Key Concept

Crossover study design and washout periods
Rate this question

Topics

Study Design

More questions from this topic